Figure 3
Loss of smooth muscle cell Plpp3 reduces abdominal aortic aneurysm development. (A) Systolic blood pressure measurements from fl/fl (n = 4) and Sm22-Δ (n = 3) mice treated with AngII for 4 weeks. (B) Plasma cholesterol at baseline and post-4 week AngII were measured in fl/fl (n = 10) and SM22-Δ (n = 7) mice. (C) Abdominal aortic diameter measurements of fl/fl (n = 10) and SM22-Δ (n = 8) were measured using ultrasound at baseline and 4 week AngII. *P < 0.001, Two-way ANOVA, Holm-Sidak, all pairwise multiple comparison. (D) Percent incidence of AAA in fl/fl (n = 10) and SM22-Δ (n = 7) mice treated with AngII for 4 weeks. (E) Representative images of aortas from fl/fl and SM22-Δ. (F) Representative movat pentachrome stained images of abdominal aorta from fl/fl and SM22-Δ mice following 4 week AngII treatment. (G) Representative H&E stained images of abdominal aorta from fl/fl and SM22-Δ mice following 4 week AngII treatment.
